The human prostate cancer LNCaP and androgen-independent bone metastasis PC-3 cell lines were obtained from the American Type Culture Collection (ATCC). The cell subline PC-3-PIP, modified to express high levels of PSMA, was kindly provided by Dr W. Heston (Cleveland, USA). See more All chemicals were purchased from Sigma-Aldrich unless otherwise specified. DOTA (S-2-(4-benzyl-isothiocyanate)−1,4,7,10-tetra-azacyclododecane tetraacetic-acid) was purchased from Macrocyclics. ScFvD2B (MW 27 … See more To establish the minimal amount of DOTA-scFvD2B necessary to obtain 177Lu-DOTA-scFvD2B (177Lu-scFvD2B) with a high radiochemical yield, 0.5 mL of 0.25 M sodium acetate buffer … See more Animal studies were performed according to national and international ethical regulations, for the handling of laboratory animals (Official Mexican Norm 062-ZOO-1999). This research was approved by the CICUAL-ININ Ethics … See more To assess the 177Lu-radiotracers cell uptake, a solution containing 1 × 105 LNCaP or PC-3 cells diluted in 1 mL of fresh medium was added to a glass tube and incubated with 10 µL (2 MBq and 120 pmol) of 177Lu … See more WebSingle chain variable D2B antibody fragments (scFvD2Bs) exhibit high affinity binding to prostate specific membrane antigens overexpressed in metastatic prostate cancer (PC). …
Development of Lu-scFvD2B as a Potential Immunotheranostic …
WebMethods: 177 Lu-scFvD2B, 177 Lu-PSMA-617, and 177 Lu-iPSMA were prepared and their radiochemical purity determined. Biodistribution studies of each radiopharmaceutical … WebIn vitro, (177)Lu-scFvD2B disclosed a higher binding and internalization in LNCaP (PSMA-positive) compared to PC3 (negative control) human PCa cells. In vivo studies in healthy … richard blalock ii md murray ky
D2B antibody and its scFvD2B fragment in nanomedicine
WebJun 16, 2024 · In vitro, 177Lu-scFvD2B disclosed a higher binding and internalization in LNCaP (PSMA-positive) compared to PC3 (negative control) human PCa cells. In vivo … WebSep 24, 2024 · (b) scFvD2B is portrayed as a portion of D2B protein that is small in size. This structure most likely causes monovalent binding interactions that maximise scFvD2B … WebCancers 2024, 13, 779 2 of 26 introduced docetaxel (chemotherapy, approved in 2004/2007), cabazitaxel (chemother-apy, approved in 2010/2011), sipuleucel-T (autologous … richard blanchard 1690